Spero Therapeutics, Inc. announced that the FDA has granted approval for Utebzi (tebipenem pivoxil), the first and only oral carbapenem antibiotic approved for treating complicated urinary tract infections (cUTIs), including pyelonephritis, in adult patients with limited or no alternative oral treatment options. The approval was received ahead of the PDUFA date of June 18, 2026. Spero Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing antibiotic treatments.
